Routes of
administration Oral PubChem CID 3034011 Molar mass 523.458 g/mol | CAS Number 116057-75-1 ChemSpider 2298565 Route Oral administration | |
 | ||
Biological half-life Acute: 15 hours
Chronic: 23 days Synonyms CB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen | ||
Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a non-steroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed. It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due insufficient effectiveness in both cases.
Contents
How to pronounce idoxifene
Synthesis
A large-scale chemical synthesis of idoxifene has been devised.
References
Idoxifene Wikipedia(Text) CC BY-SA